Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review)
Authors:
- 31 August 2016
- journal article
- review article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 38 (4) , 1021-1029
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 66 references indexed in Scilit:
- Normalization of the Vasculature for Treatment of Cancer and Other DiseasesPhysiological Reviews, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formationProceedings of the National Academy of Sciences, 2009
- Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsNeuro-Oncology, 2008
- Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivoInternational Journal of Cancer, 2007
- Macrophage migration and gene expression in response to tumor hypoxiaInternational Journal of Cancer, 2005
- Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphateBlood, 2005
- Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissuesBlood, 2004
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994